Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Key Stats

Today's Range
$25.59
$25.59
50-Day Range
$25.55
$25.59
52-Week Range
$9.90
$25.61
Volume
600 shs
Average Volume
1.29 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.24
Consensus Rating
Hold

Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Deciphera Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
16th Percentile Overall Score

DCPH MarketRank™: 

Deciphera Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat, and ranked 922nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.15) to ($1.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Deciphera Pharmaceuticals has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for DCPH.
  • Dividend Yield

    Deciphera Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Deciphera Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for DCPH.
    • Insider Buying vs. Insider Selling

      In the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 4.67% of the stock of Deciphera Pharmaceuticals is held by insiders.

    • Percentage Held by Institutions

      70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Deciphera Pharmaceuticals' insider trading history.
    Receive DCPH Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    DCPH Stock News Headlines

    Crypto Crash Ahead? (27 Experts Weigh In)
    Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
    See More Headlines

    DCPH Stock Analysis - Frequently Asked Questions

    Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its earnings results on Tuesday, February, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The firm's quarterly revenue was up 32.9% on a year-over-year basis.

    Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

    Company Calendar

    Last Earnings
    2/06/2024
    Today
    11/01/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:DCPH
    Fax
    N/A
    Employees
    300
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $23.24
    High Stock Price Target
    $26.00
    Low Stock Price Target
    $16.00
    Potential Upside/Downside
    -9.2%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.13
    Research Coverage
    8 Analysts

    Profitability

    Net Income
    $-194,940,000.00
    Net Margins
    -108.86%
    Pretax Margin
    -108.62%

    Debt

    Sales & Book Value

    Annual Sales
    $174.91 million
    Book Value
    $4.38 per share

    Miscellaneous

    Free Float
    82,438,000
    Market Cap
    $2.21 billion
    Optionable
    Optionable
    Beta
    0.19
    Ten Starter Stocks For Beginners to Buy Now Cover

    Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

    Get This Free Report

    This page (NASDAQ:DCPH) was last updated on 11/2/2024 by MarketBeat.com Staff
    From Our Partners